Broxitalamic acid is tribromobenzoic acid derivative used as x-ray contrast medium

Enfenamic acid (under brand name tromaril) is an anthranilic acid derivative with potent anti-inflammatory, anti-arthritic, analgesic and antipyretic actions. It has additional unique property of anti-platelet aggregation activity, without disturbing any other blood coagulation factors. It also differs from other non-steroidal anti-inflammatory agents like indomethacin, in producing diuresis and natriuresis. In the clinical study, tromaril showed itself as a strong and effective drug for use in various eye diseases.

Cicrotoic acid is a biochemical drug that acts on bile flow and liquid composition of human bile.

Fuzlocillin is a penicillin antibiotic. This semisynthetic acylureidopenicillin with antibacterial activity binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Fuzlocillin (furazlocillin), has been shown to be highly specific for the FtsI gene. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing the cell to break down (cell lysis). Among the acylureidopenicillins, furaclocillin exerts increased activity against Escherischia coli, Klebsiella, Proteus and Pseudomonas aeruginosa.

Merimepodib has immunosuppressive activity. It targets hepatitis C indirectly through the inhibition of inositol monophosphate dehydrogenase, which exerts an acute antiproliferative effect on lymphocyte proliferation due to their almost exclusive dependence on the de novo pathway for synthesis of guanosine. Phase II clinical trial study of merimepodib for the treatment of HCV infection and psoriasis were completed. The poor pharmacokinetic-pharmacodynamic results have resulted in discontinuation of clinical trials.

Nikkomycin Z is an antifungal drug that inhibits chitin synthase. It has been reported that it inhibits chitin synthases (Chs) 1 and 3, but not 2, of Saccharomyces cerevisiae. Later it was found that nikkomycin Z inhibited all three Chs isozymes of Candida albicans (CaChs). The IC(50) value for CaChs1 is 15 uM, for CaChs2 0.8 uM, and for CaChs3 13 uM. Nikkomycin Z is under development as an orphan product for treatment of coccidioidomycosis. Nikkomycin Z has been used in trials studying the treatment and basic science of Coccidioidomycosis. In February 2006, nikkomycin z was designated as an orphan drug for the treatment of Coccidioidomycosis.

ISOPROFEN is an anti-inflammatory agent with analgesic and antipyretic properties. Its anti-inflammatory potency is greater than that of phenylbutazone but lower than that of indomethacin. Its antipyretic action can be explained by an effect of this substance on the metabolism of arachidonic acid in the brain.

Febuverine is a spasmolytic and local anesthetic.

Daiichi Sankyo developed an inhibitor of acyl-coenzyme A:cholesterol acyltransferases (ACAT1 and ACAT2), pactimibe (also known as CS 505). Pactimibe has been used in trials phase II for reducing the progression of coronary artery disease and in patients with atherosclerosis. However, on October 26, 2005, the company made the decision to discontinue all ongoing clinical studies of pactimibe, because of the secondary endpoints that showed a lower effect of the drug on atherosclerosis than the standard of care alone and no beneficial effect on the frequency of cardiovascular events.

Nafagrel [DP 1904, SR 96325] is a thromboxane A2 synthetase inhibitor that was undergoing clinical trials with Daiichi Seiyaku, now Daiichi Pharmaceutical, for the diabetic angiopathies, lupus nephritis and Raynaud's disease in Japan. However the development of Nafagrel has been discontinued.